secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001104659-25-101390
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.06, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax enters lease assignment and asset sales with AstraZeneca for $59.8M; expects Q3 non-cash charges of $125-127M
--------------------------------------------------------------------------------

- Assignment fee $15M, parcel sale $20M, asset sale $24.8M; total $59.8M from AstraZeneca.
- Non-cash impairment of $96-98M in Q3 2025 from these transactions, plus $29M from convertible note extinguishment.
- Parcel sale closes Q4 2025; lease assignment and asset sale close Q1 2026.
- Novavax pays base rent for Jan-Jun 2026 under lease assignment; AstraZeneca responsible thereafter.
- Corporate headquarters relocated from 700 Quince Orchard Rd to 21 Firstfield Rd, Gaithersburg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925101390/0001104659-25-101390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925101390/tm2529188d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-101390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer